BINEX Co., Ltd. (KOSDAQ:053030)
South Korea · Delayed Price · Currency is KRW 12,570
+170 (1.37%)
At close: Mar 20, 2026
BINEX Revenue
In the year 2025, BINEX had annual revenue of 168.47B KRW with 29.55% growth. BINEX had revenue of 38.80B in the quarter ending December 31, 2025, with 7.89% growth.
Revenue
168.47B
Revenue Growth
+29.55%
P/S Ratio
2.38
Revenue / Employee
259.19M
Employees
650
Market Cap
400.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 168.47B | 38.42B | 29.55% |
| Dec 31, 2024 | 130.05B | -24.77B | -16.00% |
| Dec 31, 2023 | 154.82B | -1.85B | -1.18% |
| Dec 31, 2022 | 156.68B | 22.28B | 16.58% |
| Dec 31, 2021 | 134.40B | 1.42B | 1.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.40T |
| EASY BIO,Inc. | 465.24B |
| Bioneer | 320.69B |
| GC Cell | 170.13B |
| JETEMA, | 75.55B |
| HLB Therapeutics | 63.25B |
| SillaJen | 7.84B |
| Anterogen.Co.,Ltd. | 7.54B |